Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: A two-year pilot study

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Mörck, Boel ^a   Pullerits, Rille ^a   Geijer, Mats ^b,c   Bremell, Tomas ^a   Forsblad D'Elia, Helena ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HLA B27 ANTIGEN; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SACROILIAC JOINT; SHORT FORM 36; SOCIAL INTERACTION; TREATMENT RESPONSE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; TIME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HLA-B27 ANTIGEN; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SACROILIAC JOINT; SPONDYLITIS, ANKYLOSING; TIME FACTORS;

EID: 84884851753     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/289845     Document Type: Article

References (40)

1. Brandt J., Bollow M., Häberle J., Rudwaleit M., Eggens U., Distler A., Sieper J., Braun J., Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology 1999 38 9 831 836 2-s2.0-0032726541 10.1093/rheumatology/38.9.831 (Pubitemid 29507364)
2. Braun J., Bollow M., Remlinger G., Eggens U., Rudwaleit M., Distler A., Sieper J., Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis and Rheumatism 1998 41 1 58 67 10.1002/1529-0131(199801) 41:1<58::AID-ART8>3.0.CO;2-G (Pubitemid 28041923)
3. Boonen A., A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nature Clinical Practice Rheumatology 2006 2 10 546 553 2-s2.0-33749354106 10.1038/ncprheum0297 (Pubitemid 44489958)
4. Zochling J., van der Heijde D., Burgos-Vargas R., Collantes E., Davis J. C. Jr., Dijkmans B., Dougados M., Géher P., Inman R. D., Khan M. A., Kvien T. K., Leirisalo-Repo M., Olivieri I., Pavelka K., Sieper J., Stucki G., Sturrock R. D., van der Linden S., Wendling D., Böhm H., Van Royen B. J., Braun J., ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the Rheumatic Diseases 2006 65 4 442 452 2-s2.0-33645124111 10.1136/ard.2005.041137
5. van der Heijde D., Dijkmans B., Geusens P., Sieper J., DeWoody K., Williamson P., Braun J., Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis and Rheumatism 2005 52 2 582 591 2-s2.0-13444253765 10.1002/art.20852 (Pubitemid 40216323)
6. Baraliakos X., Listing J., Fritz C., Haibel H., Alten R., Burmester G., Krause A., Schewe S., Schneider M., Sörensen H., Schmidt R., Sieper J., Braun J., Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome. Rheumatology 2011 50 9 1690 1699 2-s2.0-80051920383 10.1093/rheumatology/ker194 ker194
7. Saougou I., Markatseli T. E., Voulgari P. V., Drosos A. A., Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study. Joint Bone Spine 2010 77 4 325 329 2-s2.0-77954623685 10.1016/j.jbspin.2010.02.014
8. Heldmann F., Brandt J., van der Horst-Bruinsma I. E., Landewe R., Sieper J., Burmester G. R., van den Bosch F., de Vlam K., Geusens P., Gaston H., Schewe S., Appelboom T., Emery P., Dougados M., Leirisalo-Repo M., Breban M., Listing J., Braun J., The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clinical and Experimental Rheumatology 2011 29 4 672 680 2-s2.0-80055097919
9. Tenga G., Goëb V., Lequerré T., Bacquet-Deschryver H., Daragon A., Pouplin S., Lanfant-Weybel K., Le Loët X., Dieu B., Vittecoq O., A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs. Joint Bone Spine 2011 78 1 50 55 2-s2.0-78651093827 10.1016/j.jbspin.2010.04.017
10. Maksymowych W. P., Jhangri G. S., Lambert R. G., Mallon C., Buenviaje H., Pedrycz E., Luongo R., Russell A. S., Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. Journal of Rheumatology 2002 29 5 959 965 2-s2.0-0036256691 (Pubitemid 34493501)
11. Rejón E., Giménez M. D., Mayordomo L., Rodríguez S., González M. P., Marenco J. L., Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement. Scandinavian Journal of Rheumatology 2004 33 5 323 326 2-s2.0-7044235175 10.1080/03009740310004720 (Pubitemid 39421216)
12. Sidiropoulos P., Kritikos H. D., Siakka P., Mamoulaki M., Kouroumali H., Voudouris K., Boumpas D. T., Low dose of infliximab is inadequate in most patients with spondylarthropathies. Clinical and Experimental Rheumatology 2005 23 4 513 516 2-s2.0-26844461121 (Pubitemid 41447623)
13. Keeling S., Oswald A., Mallon C., Russell A. S., Maksymowych W. P., Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup. Journal of Rheumatology 2006 33 3 558 561 2-s2.0-33644693176 (Pubitemid 43334580)
14. Jois R. N., Leeder J., Gibb A., Gaffney K., Macgregor A., Somerville M., Scott D. G. I., Low-dose infliximab treatment for ankylosing spondylitis-clinically- and cost-effective. Rheumatology 2006 45 12 1566 1569 2-s2.0-33751398480 10.1093/rheumatology/kel156 (Pubitemid 44817066)
15. Inman R. D., Maksymowych W. P., A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. Journal of Rheumatology 2010 37 6 1203 1210 2-s2.0-77953177072 10.3899/jrheum.091042
16. van der Linden S., Valkenburg H. A., Cats A., Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and Rheumatism 1984 27 4 361 368 2-s2.0-0021272107 (Pubitemid 14134775)
17. Maksymowych W. P., Inman R. D., Salonen D., Dhillon S. S., Williams M., Stone M., Conner-Spady B., Palsat J., Lambert R. G. W., Spondyloarthritis research consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Care and Research 2005 53 5 703 709 2-s2.0-26844549374 10.1002/art.21445 (Pubitemid 41463835)
18. Prevoo M. L. L., van 'T Hof M. A., Kuper H. H., van Leeuwen M. A., van de Putte L. B. A., van Riel P. L. C. M., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism 1995 38 1 44 48 2-s2.0-0028815803 10.1002/art.1780380107
19. Felson D. T., Anderson J. J., Boers M., Bombardier C., Chernoff M., Fried B., Furst D., Goldsmith C., Kieszak S., Lightfoot R., Paulus H., Tugwell P., Weinblatt M., Widmark R., Williams H. J., Wolfe F., The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis and Rheumatism 1993 36 6 729 740 2-s2.0-0027238592 (Pubitemid 23175613)
20. Pedersen S. J., Sørensen I. J., Hermann K. A., Madsen O. R., Tvede N., Hansen M. S., Thamsborg G., Andersen L. S., Majgaard O., Loft A. G., Erlendsson J., Asmussen K., Johansen J. S., Jurik A. G., Møller J., Hasselquist M., Mikkelsen D., Skjødt T., Hansen A., Østergaard M., Responsiveness of the ankylosing spondylitis disease activity score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor inhibitors. Annals of the Rheumatic Diseases 2010 69 6 1065 1071 2-s2.0-77953710657 10.1136/ard.2009.111187
21. Garrett S., Jenkinson T., Kennedy L. G., Whitelock H., Gaisford P., Calin A., A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. Journal of Rheumatology 1994 21 12 2286 2291 2-s2.0-0028575453
22. Jenkinson T. R., Mallorie P. A., Whitelock H. C., Kennedy L. G., Garrett S. L., Calin A., Defining spinal mobility in ankylosing spondylitis (AS). The bath AS metrology index. Journal of Rheumatology 1994 21 9 1694 1698 2-s2.0-0028129277 (Pubitemid 24285485)
23. Calin A., Garrett S., Whitelock H., O'Hea J., Mallorie P., Jenkinson T., A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. Journal of Rheumatology 1994 21 12 2281 2285 2-s2.0-0028579768
24. Jones S. D., Steiner A., Garrett S. L., Calin A., The bath ankylosing spondylitis patient global score (BAS-G). The British Journal of Rheumatology 1996 35 1 66 71 2-s2.0-0029969624
25. Persson L., Karlsson J., Bengtsson C., Steen B., Sullivan M., The Swedish SF-36 health survey II. Evaluation of clinical validity: results from population studies of elderly and women in Gothenborg. Journal of Clinical Epidemiology 1998 51 11 1095 1103 2-s2.0-0032211645 10.1016/S0895-4356(98)00101- 2 (Pubitemid 28527165)
26. McHorney C. A., Ware J. E. Jr., Lu J. F., Sherbourne C. D., The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care 1994 32 1 40 66 2-s2.0-0028120266
27. Ware J. E. Jr., Sherbourne C. D., The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992 30 6 473 483 2-s2.0-0026877917
28. Sullivan M. K., Taft C., Ware J., SF-36 Health Survey: Swedish Manual and Interpretation Guide 2002 2nd
29. de Vries H. S., van Oijen M. G. H., Driessen R. J. B., de Jong E. M. G. J., Creemers M. C. W., Kievit W., de Jong D. J., Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. The British Journal of Clinical Pharmacology 2011 71 1 7 19 2-s2.0-78650006702 10.1111/j.1365-2125.2010.03760.x
30. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gromnica-Ihle E., Kellner H., Krause A., Schneider M., Sörensen H., Zeidler H., Thriene W., Sieper J., Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. The Lancet 2002 359 9313 1187 1193 2-s2.0-0037029430 10.1016/S0140-6736(02)08215-6 (Pubitemid 34304258)
31. Chen J., Liu C., Lin J., Methotrexate for ankylosing spondylitis. Cochrane database of systematic reviews 2006 4 CD004524 2-s2.0-39049174015
32. Pérez-Guijo V. C., Cravo A. R., Castro M. D. C., Font P., Muñoz-Gomariz E., Collantes-Estevez E., Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 2007 74 3 254 258 2-s2.0-34248232034 10.1016/j.jbspin.2006.08.005 (Pubitemid 46720042)
33. Mulleman D., Lauféron F., Wendling D., Ternant D., Ducourau E., Paintaud G., Goupille P., Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Research and Therapy 2011 13 3, article R82 2-s2.0-79957793717 10.1186/ar3350
34. Breban M., Ravaud P., Claudepierre P., Baron G., Henry Y., Hudry C., Euller-Ziegler L., Pham T., Solau-Gervais E., Chary-Valckenaere I., Marcelli C., Perdriger A., Le Loët X., Wendling D., Fautrel B., Fournié B., Combe B., Gaudin P., Jousse S., Mariette X., Baleydier A., Trape G., Dougados M., Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis and Rheumatism 2008 58 1 88 97 2-s2.0-38149024172 10.1002/art.23167
35. Sampaio-Barros P. D., Costallat L. T. L., Bertolo M. B., Neto J. F. M., Samara A. M., Methotrexate in the treatment of ankylosing spondylitis. Scandinavian Journal of Rheumatology 2000 29 3 160 162 2-s2.0-0034544630 10.1080/030097400750002021 (Pubitemid 32014428)
36. Valesini G., Iannuccelli C., Marocchi E., Pascoli L., Scalzi V., Di Franco M., Biological and clinical effects of anti-TNF treatment. Autoimmunity Reviews 2007 7 1 35 41 2-s2.0-35448935612 10.1016/j.autrev.2007.03.003 (Pubitemid 47633389)
37. Smolen J. S., Emery P., Infliximab: 12 years of experience. Arthritis Research and Therapy 2011 13 1, article S2 2-s2.0-79958145733 10.1186/1478-6354-13-S1-S2
38. Braun J., Brandt J., Listing J., Zink A., Alten R., Burmester G., Golder W., Gromnica-Ihle E., Kellner H., Schneider M., Sörensen H., Zeidler H., Reddig J., Sieper J., Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis and Rheumatism 2003 48 8 2224 2233 2-s2.0-0042072982 10.1002/art.11104 (Pubitemid 36959203)
39. Braun J., Deodhar A., Dijkmans B., Geusens P., Sieper J., Williamson P., Xu W., Visvanathan S., Baker D., Goldstein N., van der Heijde D., Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis and Rheumatism 2008 59 9 1270 1278 2-s2.0-52249095365 10.1002/art.24001
40. Landewé R. B. M., Hermann K. A., van der Heijde D. M. F. M., Baraliakos X., Jurik A., Lambert R. G., Østergaard M., Rudwaleit M., Salonen D. C., Braun J., Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experiment. Journal of Rheumatology 2005 32 10 2050 2055 2-s2.0-26444554970 (Pubitemid 41429043)